Support Alert

Drug safety update: Corticosteroids: rare risk of central serous chorioretinopathy

The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a drug safety update on the rare risk of central serous chorioretinopathy after local administration of corticosteroids via inhaled and intranasal, epidural, intra-articular, topical dermal, and periocular routes, as well as with systemic administration.

Pharmacists are advised to inform patients to report any blurred vision or other visual disturbances during corticosteroid treatment.

Further details of the drug safety update and advice for healthcare professionals are available on the MHRA website.